On the basis of the results of previous national and international trials and studies, the Renal Tumour Study Group of the International Society of Paediatric Oncology (SIOP–RTSG) has developed a new study protocol for paediatric renal tumours: the UMBRELLA SIOP–RTSG 2016 protocol (the UMBRELLA protocol). Currently, the overall outcomes of patients with Wilms tumour are excellent, but subgroups with poor prognosis and increased relapse rates still exist. The identification of these subgroups is of utmost importance to improve treatment stratification, which might lead to reduction of the direct and late effects of chemotherapy. The UMBRELLA protocol aims to validate new prognostic factors, such as blastemal tumour volume and molecular markers, to further improve outcome. To achieve this aim, large, international, high-quality databases are needed, which dictate optimization and international harmonization of specimen handling and comprehensive sampling of biological material, refine definitions and improve logistics for expert review. To promote broad implementation of the UMBRELLA protocol, the updated SIOP–RTSG pathology and molecular biology protocol for Wilms tumours has been outlined, which is a consensus from the SIOP–RTSG pathology panel.

在以往国内和国际试验和研究结果的基础上，国际儿科肿瘤学会肾肿瘤研究组（SIOP-RTSG）制定了新的儿科肾肿瘤研究方案：UMBRELLA SIOP-RTSG 2016方案（UMBRELLA 协议）。目前，肾母细胞瘤患者的总体预后良好，但预后较差、复发率较高的亚组仍然存在。这些亚组的识别对于改善治疗分层至关重要，这可能会减少化疗的直接和后期影响。 UMBRELLA 方案旨在验证新的预后因素，例如胚基肿瘤体积和分子标记，以进一步改善结果。为了实现这一目标，需要大型、国际、高质量的数据库，这需要优化和国际协调样本处理和生物材料的综合采样，完善定义并改善专家评审的后勤工作。为了促进 UMBRELLA 方案的广泛实施，概述了更新的 Wilms 肿瘤 SIOP-RTSG 病理学和分子生物学方案，这是 SIOP-RTSG 病理学小组的共识。